



J Cutan Aesthet Surg. 2013 Apr-Jun; 6(2): 63–64.
doi: 10.4103/0974-2077.112664: 10.4103/0974-2077.112664

PMCID: PMC3764764
PMID: [24023425](#)

A New Era of Vitiligo Research and Treatment

[Davinder Parsad](#)

Department of Dermatology, Post-graduate Institute of Medical Education and Research, Chandigarh, India

Address for correspondence: Dr. Davinder Parsad, Department of Dermatology, Post-graduate Institute of Medical Education & Research, Chandigarh - 160 012, India. E-mail: parsad@me.com

Copyright : © Journal of Cutaneous and Aesthetic Surgery

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This is a very exciting phase of vitiligo research in which vitiligo is being tackled by multipronged attacks in the form of advancement in basic research, genetics and treatment including surgical management. In order to achieve the ultimate goal of total stability and complete repigmentation, there is a need to define a roadmap and roadblocks.

Vitiligo Global Issues Consensus Conference (VGICC) recently revised the classification of the disease.[1] There are still several unmet needs as pathophysiology or prognosis based classifications would be more useful. Recent progress in genetics of generalized vitiligo provide insights into underlying pathogenetic mechanisms and incrimination of vitiligo susceptibility genes that controls important aspects of immune regulation.[2] Recent data has clearly supported that vitiligo is a T-cell mediated autoimmune disease.[3,4] Heat shock protein 70 (HSP70) plays a central non redundant role in precipitating of depigmentation in vitiligo.[5] Mosenson *et al.* in a very promising study recently showed that vitiligo can be reversed through immune targeting with mutant HSP70. [6]

The bottle neck in vitiligo research is defining stability in vitiligo. Many attempts have been made to define it based on clinical, histological or immunological parameter with variable results.[7,8] It seems that disease activity in vitiligo is a dynamic process and only predictable thing about stability in non-segmental vitiligo is its unpredictability. VGICC recommends disease stability be best assessed based on the stability of individual lesions rather than the overall stability of the disease as the latter is difficult to define precisely and reliably.[1]

There are two main goals of any vitiligo treatment; first is to stop the arrest of further depigmentation and second is to induce repigmentation. The first goal can only be achieved fully if we could unravel the mechanisms underlying the disappearance of melanocytes in vitiligo. If this can be achieved repigmentation should be rather simple to accomplish with a combination of medical and/or surgical treatment. Unfortunately, in the literature there are only few studies which have taken into consideration the disease activity as most of the published studies discussed repigmentation as the main outcome. Phototherapy, topical calcineurin inhibitors and topical steroids are still the mainstay of medical treatment of vitiligo. In a recent preliminary study, afamelanotide (16 mg subcutaneous implant) along with Narrowband UVB has given promising results.[9] Further, controlled studies are required to confirm its efficacy and define its role in the management of vitiligo.

Surgical methods are emerging as an important solution for stable vitiligo refractory to medical treatment. Over the years vitiligo surgery has gained steady importance with more and more improved techniques proving their effectiveness. Non-cultured epidermal cell suspension (NCES) is emerging as the first line of surgical management of stable vitiligo.[10] Major advantages of NCES are that a smaller amount of donor skin is needed to cover large recipient area, little postoperative pain and discomfort, easier placement of cellular graft, excellent color match. Mohanty *et al.* used follicular unit extraction to tap the melanocytes reservoir in the hair follicle in the surgical management of vitiligo.[11] There are many differences between epidermal and hair follicle melanocytes. Epidermal melanocytes mainly consist of a homogeneous population of highly dendritic and uniformly weakly pigmented cells, whereas hair follicle melanocyte consists of at least three distinct sub-populations, including highly pigmented/dendritic bulbar melanocytes, less-differentiated tripolar cells, and an undifferentiated amelanotic bipolar sub-population. In addition, hair follicle melanocytes expressed some antigens associated with alopecia areata, but not antigens associated with vitiligo. This could be an added advantage of repigmentation induced by using hair follicle melanocytes and long-term follow-up is required for assessing the stability of repigmentation.

In this new era of vitiligo research we are looking forward to the development of new molecules aimed at vitiligo rather than borrowing from the agents used for other diseases. New exciting options are being explored as more reservoirs of melanocytes are being unravelled like dermal stem cells.

REFERENCES

1. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. *Pigment Cell Melanoma Res.* 2012;25:E1–13. [PMCID: PMC3511780] [PubMed: 22417114]
2. Spritz RA. Six decades of vitiligo genetics: Genome-wide studies provide insights into autoimmune pathogenesis. *J Invest Dermatol.* 2012;132:268–73. [PMCID: PMC3258303] [PubMed: 21993561]
3. van den Boorn JG, Konijnenberg D, Delleman TA, van der Veen JP, Bos JD, Melief CJ, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. *J Invest Dermatol.* 2009;129:2220–32. [PubMed: 19242513]

4. Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1 β processing via the NLRP1 inflammasome. *Proc Natl Acad Sci U S A*. 2013;110:2952–6. [PMCID: PMC3581876] [PubMed: 23382179]
5. Denman CJ, McCracken J, Hariharan V, Klarquist J, Oyarbide-Valencia K, Guevara-Patiño JA, et al. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. *J Invest Dermatol*. 2008;128:2041–8. [PMCID: PMC3778919] [PubMed: 18337834]
6. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. *Sci Transl Med*. 2013;5:174ra28. [PMCID: PMC3912753] [PubMed: 23447019]
7. Benzekri L, Gauthier Y, Hamada S, Hassam B. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. *Br J Dermatol*. 2013;168:265–71. [PubMed: 22963656]
8. Rao A, Gupta S, Dinda AK, Sharma A, Sharma VK, Kumar G, et al. Study of clinical, biochemical and immunological factors determining stability of disease in patients with generalized vitiligo undergoing melanocyte transplantation. *Br J Dermatol*. 2012;166:1230–6. [PubMed: 22329760]
9. Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. *JAMA Dermatol*. 2013;149:68–73. [PubMed: 23407924]
10. Budania A, Parsad D, Kanwar AJ, Dogra S. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: A randomized study. *Br J Dermatol*. 2012;167:1295–301. [PubMed: 22897617]
11. Mohanty S, Kumar A, Dhawan J, Sreenivas V, Gupta S. Noncultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo. *Br J Dermatol*. 2011;164:1241–6. [PubMed: 21275943]